

DAFTAR PUSTAKA

American Cancer Society. Breast cancer facts & figures 2017-2018. Atlanta: American Cancer Society Inc.; 2017.

American Society of Health-System Pharmacists. AHFS Drug Information Essential. Maryland: AHFS; 2015.

Angahar, LT. An overview of breast cancer epidemiology, risk factor, pathophysiology, and cancer risk reduction. *MOJ Biol Med*. 2017; 1(4).

Agustini DD, Surahman E, Abdulah R. Kualitas hidup pasien kanker payudara dengan terapi kombinasi fluorouracil, doxorubicin, dan cyclophosphamide. *Jurnal Farmasi Klinik Indonesia*. 2015; 4(3): 175-185.

Arfiani RF, Susilo DH, Suprapti BS. Comparison of the antiemetics effectiveness between granisetron and dexamethasone with ondansetron and dexamethasone in acute-phase chemotherapy patients. *Folia Medica Indonesiana*. 2016; 52(3): 185-192.

Azizah N. Evaluasi efektivitas antiemetik pada pasien kanker payudara pasca kemoterapi di RSUP Dr. Wahidin Sudirohusodo Makassar. [Skripsi]. Makassar: Universitas Islam Negeri Alauddin; 2017.

Baglama B dan Atak IE. Relationship between posttraumatic growth and demographic and clinical factors among turkish cypriot breast cancer survivors. *Procedia-Social and behavioral sciences*. 2015; 205: 709-716.

Barni S, Petrelli F, Cabiddu M. Cardiotoxicity of antiemetic drugs in oncology: an overview of the current state of the art. *Critical Review in Oncology/Hematology*. 2016.

Basch E, Prestud AA, Hesketh PJ, Kris MG, Feyer PC, Somerfield MR, Chesney M, Clark-Snow RA, Flaherry AM, Freundlich B, Morrow G, Rao KV, Schwartz RN, Lyman GH. Antiemetics: american society of clinical oncology clinical practice guideline update. *Journal of Clinical Oncology*. 2011; 29(31).

British Medical Association. British National Formulary 61. London: Pharmaceutical Press; 2011.

Brown LD. Cellular mechanisms of chemotherapy dalam *Clinical Guide to Antineoplastic Therapy: A Chemotherapy Handbook*. Oncology Nursing Society; 2015.

Chan VTC dan Yeo W. Antiemetic therapy options for chemotherapy-induced nausea and vomiting in breast cancer patients. *Breast Cancer: Target and Therapy*. 2011; 3: 151-160.

Drugsite Trust. Drug Interaction Checker. Diakses pada tanggal 23 November 2018 dari : http://www.drugs.com/drug_interactions.html

Dennis DT, Inglesby TV, Henderson DA, Barlett JG, Ascher MS, Eitzen E, *et al*. Tularemia as a biological weapon: medical and public health management. *JAMA*. 2001, 288.

Dewi AP. Evaluasi penggunaan antiemetik pada pengobatan kanker payudara di instalasi rawat inap RSUD Dr. Moewardi Surakarta pada tahun 2010. [Skripsi]. Surakarta: Universitas Sebelas Maret; 2011.

Departemen Obstetrik dan Ginekologi Fakultas Kedokteran Universitas Padjadjaran. *Bandung Controversies and Consensus in Obstetrics & Gynecology*. Jakarta: CV. Sagung Seto; 2013.

Encicon W dan Davidoff AJ. Changes in antiemetic overuse in response to choosing wisely recommendations. *JAMA Oncology*. 2016.

Faria C, Li X, Nagl N, Knoth RL, McBride A. 5-HT₃ receptor antagonist effects in cancer patients with multiple risk factor. *The American Journal of Pharmacy Benefits*. 2015; 7(2).

Finch GL, LA BN. Cancer chemotherapeutic agents. *Encyclopedia of Toxicology*. 2014; 1: 630-641.

Firdaus VRP, Asri A, Khambri D, Harahap WA. Hubungan grading histopatologi dan infiltrasi limfovaskular dengan sub tipe molekuler pada kanker payudara invasif di bagian bedah RSUP Dr. M. Djamil Padang. *Jurnal Kesehatan Andalas*. 2016; 5(1): 165-172.

Galbraith A, Bullock S, Manias E, Hunt B, Richard A. *Fundamentals of Pharmacology: An Applied Approach for Nursing and Health* (2nd Edition). United Kingdom: Pearson Prentice Hall; 2007.

Gibbons A dan Groarke A. Coping with chemotherapy for breast cancer: asking women what works. *European Journal of Oncology Nursing*. 2018; 35: 85-91.

Gitawati R. Interaksi obat dan beberapa implikasinya. *Media Litbang Kesehatan*. 2008; 18(4): 175-184.

Hariyanto BEP, Mantik MFJ, Wahani A. Kejadian muntah pada penderita kanker yang menjalani pengobatan kemoterapi di RSUP Prof. Dr. R. D. Kandou Manado. *Journal e-Clinic*. 2015; 3(3).

Heri RI. Karakteristik Pasien Kanker Payudara di RS Wahidin Sudirohusodo periode Juni-November 2017.[Skripsi] Makassar: Universitas Hasanuddin; 2017.

Hesketh PJ. Drug therapy chemotherapy-induced nausea and vomiting. New England. Journal Medicine. 2008; 358:2482- 2494.

Hoskins P. Guidelines for prevention and treatment of chemotherapy-induced nausea and vomiting in adults. BC Cancer Agency. 2012.

Husband A dan Worsley A. Nausea and vomiting- pharmacological management. Hospital Pharmacist. 2007; 4.

International Agency for Research on Cancer. GLOBOCAN 2012: Estimated Cancer Incidence Mortality and Prevalence Worldwide in 2012. Diakses pada 24 Maret 2018 dari: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx.

Jordan K, Sippel C, Schmoll HJ. Guidelines for antiemetic treatment of chemotherapy-induced nausea and vomiting: past, present, and future recommendations. The Oncologist. 2007; 12: 1143-1150.

Kator S dan Kim SS. Ondansetron and the risk of QTc prolongation. The Journal for Nurse Practitioners. 2015; 11(4): 478-479.

Katzung BG, Masters SB, Trevor AJ. Farmakologi Dasar dan Klinik Volume 2 Edisi 12. Jakarta: EGC; 2016.

Kemenkes RI. Modul Penggunaan Obat Rasional. Jakarta: Kemenkes RI; 2011.

Kemenkes RI. Riset Kesehatan Dasar: Riskesdas 2013. Jakarta: Kemenkes RI; 2013.

Kumar A dan Kumar A. Antiemetics: a review. International Journal Pharmaceutical Sciences and Research. 2013; 4(1): 113-123.

Maria IL, Sainal AA, Nyorong M. Risiko gaya hidup terhadap kejadian kanker payudara pada wanita. Jurnal MKMI. 2017; 13(2): 157-166.

Medscape. Drugs, OTCs & Herbals. Diakses 1 April 2018 dari <http://reference.medscape.com/drugs>

Medscape. Drug Interaction Checker. Diakses 20 November 2018 dari <http://reference.medscape.com/drug-interactionchecker>

Medical Mini Notes. Basic Pharmacology & Drug Note. Makassar: MMN; 2017.

Nasif H, Junaidi, Muchtar H. Efektifitas antiemetik pada pasien yang menggunakan sitostatika pascabedah pada berbagai jenis kanker di RSUD Dr.

Achmad Mochtar Bukittinggi. Jurnal Sains dan Teknologi Farmasi. 2011; 16(2): 121-127.

Navari R. Overview of the update antiemetic guidelines for chemotherapy-induced nausea and vomiting. Elsevier. 2007; 4.

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Antiemetogenik. NCCN; 2017.

Nurhayati B dan Darmawati S. Bahan Ajar Teknologi Laboratorium Medis (TLM): Biologi Sel dan Molekuler. Jakarta: Kemenkes RI; 2017.

Nurhayati. Faktor-faktor risiko yang berhubungan dengan kejadian kanker payudara di rumah sakit umum daerah kota padangsidempuan tahun 2016. Jurnal Warta. 2018; 56.

Paul EP, Behanan A, Eapen BA, James A, Sherief SH, Palanisamy MK, Sivakumar T. A study on evaluation of anti-emetics in the prevention of chemotherapy induced nausea and vomiting in cancer patients in a tertiary care hospital. Indian Journal of Pharmacy Practice. 2017; 10(1).

Pangesti DN dan Sofiani Y. Efektifitas perbandingan pemberian minuman dingin terhadap penurunan sensasi mual dan muntah setelah kemoterapi pada klien kanker payudara di RS Umum Dr. H. Abdul Moeloek Propinsi Lampung. Jurnal Kesehatan. 2016; 7(2): 189-19.

Perwitasari DA. Kajian penggunaan antiemetika pada pasien kanker dengan terapi sitostatika di rumah sakit Yogyakarta. Majalah Farmasi Indonesia. 2006;17(2).

Preston CL. Stockley's Drug Interactions. London: Pharmaceutical Press; 2016.

Price SA dan Wilson LM. Patofisiologi: Konsep Klinis Proses-Proses Penyakit Edisi 6 Volume 2. Jakarta: EGC; 2005.

Rahmatya A, Khambri D, Mulyani H. Hubungan usia dengan gambaran klinikopatologi kanker payudara di bagian bedah RSUP Dr. M. Djamil Padang. Jurnal Kesehatan Andalas. 2015; 4(2).

Roila F, Molassiotis A, Herrstedt J, Aapro M, Gralla RJ, Bruera E, Clark-Snow RA et al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Annals of Oncology. 2016; 27(5).

Shinta NR dan Surarso B. Terapi mual muntah pasca kemoterapi. Jurnal THT-KL. 2016; 9(2): 74-83.

Siregar CJP dan Kumolosari E. Farmasi Klinik: Teori dan Terapan. Jakarta: EGC; 2005.

Sweetman, SC. Martindale: The Drug Complete Reference (36th Edition). London: Pharmaceutical Press; 2009.

Tanaka H, Matsushima H, Mizumoto N, Takashima A. Classification of chemotherapeutic agents based on their differential *in vitro* effects on dendritic cells. Cancer Res. 2009; 69(17): 6978-6986.

Tjay TH dan Rahardja K. Obat-Obat Penting Edisi Ke-VI. Jakarta: PT Elex Media Komputindo; 2007.

Umar RM. Drug-drug interactions between antiemetics used in cancer patients. Journal of Oncological Sciences. 2018; xx: 1-5

Utaminigrum W, Hakim L, Raharjo B. Evaluasi kepatuhan dan respon mual muntah penggunaan antiemetik pada pasien kanker payudara yang menjalani kemoterapi di RSUD Prof. Dr. Margono Soekarjo. Pharmacy. 2013; 10(2).

World Health Organization. Rational Use of Medicine. Diakses 7 Maret 2018 dari http://www.who.int/medicines/rational_use/en/

Yang CK, Wu CE, Liaw CC. Combination of palonosetron, aprepitant, and dexamethasone as primary antiemetic prophylaxis for cisplatin-based therapy. Biomedical Journal. 2016; 39.

Yeo W, Mo FKF, Suen JJS, Ho WM, Chan SL, Lau W, Koh J, *et al.* A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in chinese breast cancer patients receiving moderately emetogenic chemotherapy. Breast Cancer Res Treat. 2009; 113(3).

Yulianti SAS. Faktor-faktor yang berhubungan dengan kejadian kanker payudara di RSUP Dr. Wahidin Sudirohusodo Makassar. [Skripsi]. Makassar UIN Alauddin 2010.

Yulianti I, Setyawan HS, Sutiningsih D. Faktor-faktor risiko kanker payudara (studi kasus pada rumah sakit ken Saras semarang. Jurnal Kesehatan Nasional (e-journal). 2016; 4(4): 401-410.